InVivo Therapeutics (NSDQ:NVIV) said today it added Stanford Medicine as the 34th clinical in the Inspire study of its neuro-spinal scaffold.
The Cambridge, Mass.-based company’s neuro-spinal scaffold is a novel, biodegradable device designed to be surgically implanted following acute spinal cord injuries to act as a physical substrate for nerve sprouting.
Dr. Atman Desai has been named principal investigator at the site, the company said.
“We are pleased to welcome one of the most recognized hospitals in the world to the Inspire study. We look forward to working with Stanford Medicine and Dr. Desai, especially given Dr. Desai’s expertise in spinal cord injury treatment,” CEO & chair Mark Perrin said in a prepared statement.
Yesterday, InVivo said it added its 1st UK-based site to the Inspire study at Middlesbrough’s James Cook University Hospital. The company said Dr. Manjunath Prasad will join the study at the site, within the Golden Jubilee Regional Spinal Cord Injuries Centre at the hospital.
